Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

Next Previous
Trial Profile

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Acronyms POSEIDON
  • Sponsors Aimmune Therapeutics; Stallergenes Greer plc

Most Recent Events

  • 28 Feb 2025 According to a Stallergenes Greer media release, company announced the launch of Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in the U.S to treat toddler patients, ages 1 through 3 years, with a confirmed diagnosis of peanut allergy.
  • 09 Jan 2025 According to a Stallergenes Greer media release, company announced that the European Commission (EC) has approved the extension of indication of Palforzia (defatted powder of Arachis hypogaea L., semen (peanut)) for the treatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. The marketing authorisation covers all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein and Norway).
  • 30 Jul 2024 According to a Stallergenes Greer media release, based on the results form this trial the U.S Food and Drug Administration (FDA) has approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], for the treatment of toddlers (ages 1-3 years) with a confirmed diagnosis of a peanut allergy. This approval expands the January 2020 FDA approval for patients ages 4-17 years.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top